THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM

被引：1
|
作者：
Schroeder, M. [1 ]
Johansen, P. [2 ]
Thompson, G. [1 ]
Willis, M. [3 ]
Neslusan, C. [4 ]
机构：
[1] Hanssen Ciiag UK, High Wycombe, Bucks, England
[2] Swedish Inst Hlth Econ IHE, Lund, Sweden
[3] Swedish Inst Hlth Econ, Lund, Sweden
[4] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.694
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB71
引用
收藏
页码：A344 / A344
页数：1
相关论文
共 50 条
  • [21] Blood Pressure (BP) Effects of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Pfeifer, Michael
    Townsend, Raymond
    Davies, Michael J.
    Vijapurkar, Ujjwala
    Ren, Jimmy
    DIABETES, 2016, 65 : A303 - A303
  • [22] SYSTEMATIC REVIEW OF COST EFFECTIVENESS OF DAPAGLIFLOZIN TREATING PATIENTS OF TYPE 2 DIABETES MELLITUS (T2DM)
    Hu, C.
    Zhang, C.
    Wang, B.
    Xu, L.
    VALUE IN HEALTH, 2018, 21 : S39 - S39
  • [23] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    DIABETES, 2013, 62 : A276 - A276
  • [24] COST-EFFECTIVENESS ANALYSIS OF XIGDUO (EXTENDED-RELEASE DAPAGLIFLOZIN-METFORMIN TABLETS) FOR MANAGING TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS
    Bao, H.
    Liu, Q.
    Peng, X.
    Xuan, J.
    VALUE IN HEALTH, 2024, 27 (06) : S122 - S122
  • [25] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [26] Achievement of Diabetes-related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Blonde, Lawrence
    Woo, Vincent
    Mathieu, Chantal
    Yee, Jacqueline
    Vijapurkar, Ujjwala
    Meininger, Gary
    DIABETES, 2014, 63 : A284 - A284
  • [27] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Usiskin, Keith
    Leiter, Lawrence A.
    Forst, Thomas
    Polidori, David
    Xie, John
    Sha, Sue
    DIABETES, 2014, 63 : A284 - A284
  • [28] Pharmacokinetics (PK) and Pharmacodynamics (PD) of Canagliflozin (CANA) in Pediatric Patients with Type 2 Diabetes Mellitus (T2DM)
    Tamborlane, William
    Polidori, David
    Di Prospero, Nicolas
    DIABETES, 2017, 66 : A371 - A371
  • [29] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [30] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA
    Shao, H.
    Shi, L.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
12345